@article {Nobile-OrazioS07.001作者={爱德华多Nobile-Orazio达里奥Cocito和斯特凡诺Jann Antonino Uncini埃托雷Beghi和乔凡尼Antonini Raffaella法齐奥和弗兰西斯卡高卢和安吉洛Schenone Ada地区和大卫。Pareyson卢西奥澳网和斯特凡诺Tamburin罗伯塔马基群落和把拉出的圭多Cavaletti和法比奥Giannini马里奥Sabatelli}, title ={一项随机、双盲、对照试验的静脉注射免疫球蛋白与静脉注射甲基强的松龙在慢性炎性脱髓鞘多神经根神经病(IMC)研究(S07.001)},体积={78}={1}补充数量,页面= {S07.001——S07.001} ={2012},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:比较6个月治疗的有效性和安全性与静脉注射免疫球蛋白(丙种球蛋白)或甲基强的松龙(IVMP)在慢性炎性脱髓鞘多神经根神经病(CIDP)。首页背景丙种球蛋白和类固醇作为初始治疗同样有效在CIDP但鲜为人知的相对风险长时间剖面。设计/方法:46个病人实现外汇/ pn标准明确的CIDP被随机分配在一个1:1比例获得丙种球蛋白(IgVena Kedrion SpA) (2 g / kg) + IVMP-placebo或IVMP (2 g) + IVIg-placebo超过四天,每月为六个月。患者随后6个月评估复发。主要终点是不同数量的患者暂停丙种球蛋白或IVMP不耐受或无效。二级终端包括改善评估尺度的差异后15天,2个月和6个月的治疗,病人的比例的差异治疗停药后恶化。结果:45例(24 IVMP丙种球蛋白和21)进行评估。一个是不适当的夹杂物排除在外。更多的病人停止IVMP(10/21, 52.5 \ %)比丙种球蛋白(3/24,12.5 \ %)(p = 0, 0085),反应迟钝或不耐受疗法。最后6个月治疗,两组同样改善了Rankin,辊筒、鹿特丹和SF-36生活质量量表和丙种球蛋白组也在湄公河委员会和感官评分和时间走10米。丙种球蛋白治疗停药后更多的病人(8/21,38.1 \ %)比IVMP(0/10)恶化,需要进一步的治疗。到12个月,一个类似的比例仍然没有改善的患者治疗的丙种球蛋白(13/24,54.1 \ %)和IVMP(10/21, 47.6 \ %)组。结论:更多的病人在IVMP比丙种球蛋白治疗的6个月期间暂停治疗因为无效或不良事件。 After therapy discontinuation, more patients treated with IVIg than with IVMP worsened and had to resume therapy.Supported by: Kedrion SpA, Italy.Disclosure: Dr. Nobile-Orazio has received personal compensation for activities with CSL Behring. Dr. Cocito has nothing to disclose. Dr. Jann has nothing to disclose. Dr. Uncini has nothing to disclose. Dr. Beghi has received personal compensation for activities with UCB Pharma as a speaker. Dr. Beghi has received personal compensation in an editorial capacity for Epilepsia. Dr. Antonini has nothing to disclose. Dr. Fazio has nothing to disclose. Dr. Gallia has nothing to disclose. Dr. Schenone has nothing to disclose. Dr. Francia has nothing to disclose. Dr. Pareyson has nothing to disclose. Dr. Santoro has nothing to disclose. Dr. Tamburin has nothing to disclose. Dr. Macchia has received personal compensation for activities with Kedrion as an employee. Dr. Guarneri has received personal compensation for activities with Kedrion Biopharmaceutical an employee. Dr. Cavaletti has nothing to disclose. Dr. Giannini has nothing to disclose. Dr. Sabatelli has nothing to disclose. Tuesday, April 24 2012, 13:00 pm-14:45 pm}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/78/1_Supplement/S07.001}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }